BioXcel's agitation drug meets main goal in at-home study
27/08/2025 12:01
Aug 27 (Reuters) - BioXcel Therapeutics BTAI.O said on Wednesday its experimental agitation drug met the main goal of a late-stage study testing it in patients with bipolar disorder or schizophrenia for at-home use. (Reporting by Bhanvi Satija, Sneha S K and Siddhi Mahatole in Bengaluru; Editing by Krishna Chandra Eluri)
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty